Immune response in influenza virus infection and modulation of immune injury by viral neuraminidase

Jiang, Hongyu; Zhang, Zongde

doi:10.1186/s12985-023-02164-2

Cited by 3 publications

(3 citation statements)

References 131 publications

(120 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Influenza virus (IV) infections or acute viral respiratory infections are highly contagious and can cause pandemics, epidemics, and outbreaks [ 143 ]. The WHO estimates that each year, seasonal influenza virus (seasonal IVs), comprising the H1N1 and H3N2 IAVs and influenza B viruses, cause between 3 and 5 million severe cases and 290,000–650,000 fatalities worldwide [ 144 ].…”

Section: Crispr/cas9 Mediated Genome Editing and Drug Resistance In R...mentioning

confidence: 99%

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Hussen,

Najmadden,

Abdullah

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Respiratory disorders are among the conditions that affect the respiratory system. The healthcare sector faces challenges due to the emergence of drug resistance to prescribed medications for these illnesses. However, there is a technology called CRISPR/Cas9, which uses RNA to guide DNA targeting. This technology has revolutionized our ability to manipulate and visualize the genome, leading to advancements in research and treatment development. It can effectively reverse epigenetic alterations that contribute to drug resistance. Some studies focused on health have shown that targeting genes using CRISPR/Cas9 can be challenging when it comes to reducing drug resistance in patients with respiratory disorders. Nevertheless, it is important to acknowledge the limitations of this technology, such as off-target effects, immune system reactions to Cas9, and challenges associated with delivery methods. Despite these limitations, this review aims to provide knowledge about CRISPR/Cas9 genome editing tools and explore how they can help overcome resistance in patients with respiratory disorders. Additionally, this study discusses concerns related to applications of CRISPR and provides an overview of successful clinical trial studies.

show abstract

Section: Crispr/cas9 Mediated Genome Editing and Drug Resistance In R...mentioning

confidence: 99%

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Hussen,

Najmadden,

Abdullah

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…Influenza A is characterised by high antigenic variation of HA and NA proteins, which results primarily from the relatively frequent mutations in their RNA. The mechanisms responsible for the antigenic variability of influenza A are the phenomena of antigenic drift or antigenic shift (4) . These changes are mediated by an enzyme responsible for RNA replication (RNA polymerase), and new mutations resulting from RNA polymerase errors may increase virulence, facilitating viral attachment to the respiratory epithelium and its replication.…”

Section: Influenza -Backgroundmentioning

confidence: 99%

Recommendations for the management of children with influenza in a primary care setting – COMPAS INFLUENZA. Update for the 2023/2024 season

Sybilski,

Mastalerz-Migas,

Jackowska

et al. 2023

Pediatr Med Rodz

View full text Add to dashboard Cite

Five years after publishing the first Polish recommendations on the management of influenza, especially after the COVID-19 pandemic, there was a need to update the recommendations. Influenza is an acute infectious disease of the respiratory tract that occurs in all age groups. The course of the disease may vary in severity and clinical picture, from asymptomatic to severe with symptoms of respiratory failure. The possibility of pandemic infections and serious complications distinguish influenza from other viral respiratory diseases. Diagnosis is most often clinical, and in justified cases additional tests may be helpful. The disease is characterised by a sudden onset with general symptoms such as fever, feeling cold, chills, headache, muscle and joint pain, malaise, lack of appetite and severe weakness. General symptoms are accompanied by respiratory manifestations. Physical examination shows no characteristic features. In outpatient settings during the epidemic season (October – April), the diagnosis should be made based on clinical symptoms and physical examination. Oseltamivir is recommended for both treatment and chemoprophylaxis. Clinical benefits are greatest when treatment is started as early as possible, within 48 hours of symptom onset. Clinical trials indicate that early treatment with oseltamivir may reduce both the duration of the disease and the risk of complications. Annual vaccination is the most effective method of preventing influenza, with severe anaphylactic reaction after previous vaccination being the only absolute contraindication.

show abstract

“…The biological activity of a phytocomplex is generally stronger than the sum of the activities of the individual active molecules, and the presence of substances with no specific activity can have a significant synergistic effect [4,5] . Inflammation and associated diseases have been reported to be a great threat to public health, as evidenced by the deadly cytokine storms often observed in influenza and COVID-19 [6][7][8][9] . Pro-inflammatory cytokines are mainly produced by activated macrophages and participate in the positive regulation of inflammatory reactions.…”

Section: Introductionmentioning

confidence: 99%

VIROSCOPE®, an ethanolic extract of medicinal plants produced in Lomé, Togo, demonstrated excellent anti-inflammatory and immune cell proliferation activities

Dossouvi,

Dossouvi

et al. 2024

Int. J. Herb. Med.

View full text Add to dashboard Cite

The World Health Organization (WHO) estimated that at least 80% of the world's population finds its main, if not exclusive, therapeutic source in plants. Inflammation and associated diseases have been reported to be a great threat to public health, as evidenced by the deadly cytokine storms observed during the latest COVID-19 pandemic. Several phytomedicines with excellent anti-inflammatory and immunostimulatory activities have been reported worldwide. Thus, this study evaluated the in vitro cytotoxicity, immune cell proliferation and immunosuppressive activities of a phytomedicine "VIROSCOPE®" produced by Viroscope SARL-U in Lomé, Togo. Cytotoxicity was assessed using the Propidium Iodide Membrane Integrity Test and interpreted according to NF EN ISO 10993-5. The immune cell proliferation property was assessed by evaluating the expression of the proliferating cell nuclear antigen (PCNA) in white blood cells by flow cytometry. Evaluation of IL-6 and TNF α production by Sandwich ELISA was used to evaluate the immunosuppressive and immunostimulatory properties of VIROSCOPE®. VIROSCOPE® demonstrated slight and mild cytotoxicity, depending on the dose. In addition, VIROSCOPE® induced excellent in vitro immune cell proliferation and showed excellent anti-inflammatory activity. All these immunomodulatory activities were dose-dependent, calling for strict compliance with the dosage. Further in vitro studies, animal model tests, and clinical trials are needed to elucidate all the therapeutic activities of VIROSCOPE® and to improve its formulation.

show abstract

Immune response in influenza virus infection and modulation of immune injury by viral neuraminidase

Cited by 3 publications

References 131 publications

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Recommendations for the management of children with influenza in a primary care setting – COMPAS INFLUENZA. Update for the 2023/2024 season

VIROSCOPE®, an ethanolic extract of medicinal plants produced in Lomé, Togo, demonstrated excellent anti-inflammatory and immune cell proliferation activities

Contact Info

Product

Resources

About